JP2020531047A - 神経疾患及び神経損傷における使用のためのｂｐｉｆｂ４タンパク質のｖｔｆｔアイソフォーム - Google Patents

神経疾患及び神経損傷における使用のためのｂｐｉｆｂ４タンパク質のｖｔｆｔアイソフォーム Download PDF

Info

Publication number
JP2020531047A
JP2020531047A JP2020530730A JP2020530730A JP2020531047A JP 2020531047 A JP2020531047 A JP 2020531047A JP 2020530730 A JP2020530730 A JP 2020530730A JP 2020530730 A JP2020530730 A JP 2020530730A JP 2020531047 A JP2020531047 A JP 2020531047A
Authority
JP
Japan
Prior art keywords
protein
disease
vtft
vector
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020530730A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531047A5 (https=
Inventor
プカ，アンニバレ・アレッサンドロ
Original Assignee
エッレジヴ１・ソチエタ・ア・レスポンサビリタ・リミタータ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エッレジヴ１・ソチエタ・ア・レスポンサビリタ・リミタータ filed Critical エッレジヴ１・ソチエタ・ア・レスポンサビリタ・リミタータ
Publication of JP2020531047A publication Critical patent/JP2020531047A/ja
Publication of JP2020531047A5 publication Critical patent/JP2020531047A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020530730A 2017-08-16 2018-08-16 神経疾患及び神経損傷における使用のためのｂｐｉｆｂ４タンパク質のｖｔｆｔアイソフォーム Pending JP2020531047A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17186528 2017-08-16
EP17186528.0 2017-08-16
PCT/EP2018/072184 WO2019034723A1 (en) 2017-08-16 2018-08-16 VTFT ISOFORM OF BPIFB4 PROTEIN INTENDED FOR USE IN NEURONAL DISEASES AND INJURIES

Publications (2)

Publication Number Publication Date
JP2020531047A true JP2020531047A (ja) 2020-11-05
JP2020531047A5 JP2020531047A5 (https=) 2021-09-24

Family

ID=59713793

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020530730A Pending JP2020531047A (ja) 2017-08-16 2018-08-16 神経疾患及び神経損傷における使用のためのｂｐｉｆｂ４タンパク質のｖｔｆｔアイソフォーム

Country Status (8)

Country Link
US (1) US12311009B2 (https=)
EP (1) EP3668891B1 (https=)
JP (1) JP2020531047A (https=)
CN (1) CN111094327A (https=)
AU (1) AU2018317807A1 (https=)
CA (1) CA3109159A1 (https=)
ES (1) ES2970198T3 (https=)
WO (1) WO2019034723A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4434534A1 (en) 2023-03-22 2024-09-25 ADvantage Therapeutics, Inc. Klotho mrna

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500829A (ja) * 2000-04-18 2004-01-15 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 新規な脂質結合タンパク質４
JP2016508036A (ja) * 2012-12-28 2016-03-17 アンニバレ・アレッサンドロ・プカ Ｂｐｉｆｂ４タンパク質の変異体

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
AU2144999A (en) * 1998-01-13 1999-08-02 Claude Gravel Viral vectors encoding neurofilament heavy proteins and their use
WO1999036560A2 (en) * 1998-01-13 1999-07-22 Julien Jean Pierre Viral vectors encoding neurofilament light proteins and their use
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
AU2002313992B2 (en) * 1998-08-31 2006-09-21 Pro-Neuron, Inc. Compositions and Methods for Treatment of Mitochondrial Diseases
AU6234700A (en) * 1999-07-27 2001-02-13 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
US6515197B1 (en) * 2000-08-24 2003-02-04 Cedars-Sinai Medical Center Transgenic mouse expressing a polynucleotide encoding a human ataxin-2 polypeptide
GB0100119D0 (en) * 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
JP2004532006A (ja) * 2001-02-08 2004-10-21 インサイト・ゲノミックス・インコーポレイテッド 細胞内シグナル伝達分子
WO2002090504A2 (en) * 2001-05-03 2002-11-14 Curagen Corporation Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
WO2003004660A1 (en) * 2001-07-03 2003-01-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods of administering vectors to synaptically connected neurons
AU2002359284A1 (en) 2001-12-17 2003-06-30 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
NZ533833A (en) * 2001-12-21 2008-01-31 Salk Inst For Biological Studi Targeted retrograde gene delivery to motor neurons
US20040092715A1 (en) * 2002-02-07 2004-05-13 Li Ding Intracellular signaling molecules
EP1489423A1 (en) * 2003-06-20 2004-12-22 Universite Louis Pasteur Use of mitochondrial uncoupling proteins for diagnostic, prevention and treatment of diseases involving neuromuscular affection
WO2005095610A1 (en) * 2004-03-31 2005-10-13 Agt Biosciences Limited Nucleic acid expressed in the hypothalamus or muscle tissue and uses thereof in diagnoses
WO2006022619A2 (en) * 2004-07-22 2006-03-02 Sequenom, Inc. Methods for identifying risk of type ii diabetes and treatments thereof
CA2584986A1 (en) * 2004-10-22 2006-05-04 Neurologix, Inc. Use of apoptosis inhibiting compounds in degenerative neurological disorders
PL1879623T3 (pl) * 2005-05-02 2013-03-29 Genzyme Corp Terapia genowa zaburzeń rdzenia kręgowego
KR20080080109A (ko) * 2005-11-04 2008-09-02 바이오겐 아이덱 엠에이 인코포레이티드 도파민성 뉴런의 신경돌기 성장 및 생존의 촉진 방법
PL2066791T3 (pl) * 2006-10-03 2013-02-28 Genzyme Corp Terapia Genowa do leczenia stwardnienia zanikowego bocznego i innych zaburzeń rdzenia kręgowego
EP2150117A4 (en) * 2007-05-02 2011-10-05 Mclean Hospital Corp METHODS AND COMPOSITIONS FOR MITOCHONDRIA REPLACEMENT THERAPY
WO2009020624A1 (en) * 2007-08-08 2009-02-12 The Board Of Trustees Of The University Of Alabama For And On Behalf Of The University Of Alabama Regulators of protein misfolding and neuroprotection and methods of use
MX2010010495A (es) * 2008-04-03 2010-10-15 Hoffmann La Roche Uso de variantes del factor de crecimiento similar a la insulina (igf-i) pegiladas para el tratamiento de trastornos neuromusculares.
WO2010071832A1 (en) 2008-12-19 2010-06-24 Nationwide Children's Hospital Delivery of polynucleotides across the blood brain barrier using recombinant aav9
WO2010088729A1 (en) * 2009-02-04 2010-08-12 University Of Tasmania Through The Menzies Research Institute Compositions and uses therefor
JP5879256B2 (ja) * 2009-05-02 2016-03-08 ジェンザイム・コーポレーション 神経変性障害のための遺伝子治療
CA2800375C (en) * 2010-05-27 2021-03-09 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
US20140147434A1 (en) * 2011-05-06 2014-05-29 Ecole Polytechnique Federale De Lausanne (Epfl) NCoR1 is a Physiological Modulator of Muscle Mass and Oxidative Function
US10815285B2 (en) * 2011-07-01 2020-10-27 University Of South Florida Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases
JP6253596B2 (ja) * 2012-02-16 2017-12-27 ザ ペン ステイト リサーチ ファンデーション アシル補酵素ａ：リゾカルジオリピン・アシル基転移酵素１（ａｌｃａｔ１）の発現、機能または活性の阻害物質を同定する方法
EP2895621B1 (en) * 2012-09-14 2020-10-21 Population Bio, Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
WO2014161095A1 (en) * 2013-04-04 2014-10-09 Crp40 Inc. Crp40 fragments for the treatment of neurological disorders
AU2014329606B2 (en) * 2013-10-01 2020-02-06 Dana-Farber Cancer Institute, Inc. Methods for the identification, assessment, prevention, and treatment of neurological disorders and diseases using Fndc5
US20170129930A1 (en) * 2014-06-19 2017-05-11 Board Of Trustees Of The University Of Arkansas Compositions and methods for modulating neuronal degeneration
US11027024B2 (en) * 2015-05-29 2021-06-08 University Of Iowa Research Foundation Methods of delivery of transgenes for treating brain diseases
CA2973891A1 (en) * 2016-07-21 2018-01-21 Stealth Biotherapeutics Corp Therapeutic compositions including modified creatine compounds and uses thereof to treat and prevent mitochondrial diseases and conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500829A (ja) * 2000-04-18 2004-01-15 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 新規な脂質結合タンパク質４
JP2016508036A (ja) * 2012-12-28 2016-03-17 アンニバレ・アレッサンドロ・プカ Ｂｐｉｆｂ４タンパク質の変異体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AM. J. PATHOL. (2016) VOL.186, ISSUE 10, SUPPLEMENT, P.S1(A1), JPN6022033984, ISSN: 0004848734 *
CIRC. RES. (2015) VOL.117, ISSUE 4, P.333-345, JPN6022033983, ISSN: 0004848735 *

Also Published As

Publication number Publication date
CN111094327A (zh) 2020-05-01
EP3668891A1 (en) 2020-06-24
US20210128681A1 (en) 2021-05-06
AU2018317807A1 (en) 2020-02-06
EP3668891B1 (en) 2023-07-26
ES2970198T3 (es) 2024-05-27
US12311009B2 (en) 2025-05-27
WO2019034723A1 (en) 2019-02-21
EP3668891C0 (en) 2023-07-26
CA3109159A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
Raulin et al. ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
JP6397391B2 (ja) 神経変性障害のための遺伝子治療
US20200338148A1 (en) Gene therapies for lysosomal disorders
EP3364997A1 (en) Methods and compositions for treating metabolic imbalance in neurodegenerative disease
JP2022523766A (ja) Ｇｒｎ関連成人発症性神経変性の治療のための組換えアデノ随伴ウイルス
CN110325219B (zh) 编码甲基-CpG结合蛋白2的重组腺相关病毒的鞘内递送
JP2015533368A (ja) 糖原貯蔵症の遺伝子療法
EP4192516A2 (en) Gene therapies for lysosomal disorders
EP3571298B1 (en) Treatment of krabbe disease with umbilical cord blood transplantion (ucbt) and increased galactocerebrosidase (galc) expression
US12404523B2 (en) Adeno-associated virus delivery of CLN3 polynucleotide
JP2020531047A (ja) 神経疾患及び神経損傷における使用のためのｂｐｉｆｂ４タンパク質のｖｔｆｔアイソフォーム
CN116457466A (zh) 用于抑制α-突触核蛋白聚集的组合物和方法
US20240058476A1 (en) Treatment of lipodystrophy
HK40031704B (en) Vtft isoform of a bpifb4 protein for use in neuronal diseases and injuries
HK40031704A (en) Vtft isoform of a bpifb4 protein for use in neuronal diseases and injuries
US20260007774A1 (en) Aav-mediated delivery of rgs10 to microglia
WO2025175135A1 (en) Modifying neurons to treat or prevent parkinson's disease
EP4720313A1 (en) Recombinant aav vectors for treating proteinopathies in central nervous system
Rieders Investigating the Dysregulation and Therapeutic Potential of Neuroprotective Stress Response Proteins in Huntington’s Disease
JP2022531177A (ja) 神経変性障害を治療するための方法

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210813

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220815

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221025

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230405